Does addition of topical calcipotriol to UVB increase the risk of irritant reactions in psoriasis? The Calcipotriol-UVB Study Group.
Molin
L
L
D000287:Administration, Topical; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D017453:Dermatitis, Irritant / Q000209:etiology*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D009824:Ointments / Q000627:therapeutic use; D011379:Prognosis; D011565:Psoriasis / Q000628:therapy*; D018570:Risk Assessment; D014467:Ultraviolet Therapy
D003879:Dermatologic Agents; D009824:Ointments; C055085:calcipotriene; D002117:Calcitriol